Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example

Over the past three decades, treatments for posttraumatic stress disorder (PTSD) have evolved from largely palliative approaches to multiple evidence-based options, most of which are cognitive–behavioural in orientation. Wagner and colleagues note that while cognitive therapies such as Cognitive Processing Therapy and Prolonged Exposure produce substantial benefit for many patients, 40–50% still have persistent PTSD after treatment, and the standard model of weekly individual psychotherapy does not suit all patients. PTSD is also conceptualised as an interpersonal problem because symptoms affect close relationships and relationship functioning can in turn maintain or ameliorate PTSD. Against this background, the investigators combined Cognitive–Behavioural Conjoint Therapy for PTSD (CBCT), a manualised dyadic intervention that targets both PTSD symptoms and relationship satisfaction, with MDMA-assisted psychotherapy. Previous MDMA studies have used non-directive supportive therapy and shown promise; however, it is unknown how MDMA would interact with an evidence-based, trauma-focused dyadic treatment. To illustrate the approach and decision-making involved in integrating these modalities, the paper presents a detailed case example from a small pilot trial in which two full-day MDMA sessions were embedded into the CBCT protocol for one couple with severe trauma history and clinically significant PTSD symptoms.

CBCT is described as a 15-module, three-phase dyadic protocol typically delivered in 75-minute sessions. Phase one (two modules) provides psychoeducation about PTSD and addresses safety barriers; phase two (five modules) develops communication and problem-solving skills and introduces behavioural approach tasks to reduce avoidance; phase three (eight modules) focuses on dyadic cognitive work to address "stuck thoughts" related to trauma (for example, acceptance, blame, trust, control, and intimacy). Out-of-session homework is prescribed to practise skills. In this case the investigators inserted two full-day MDMA sessions into the CBCT sequence: the first after module 5 (midway through phase two) to capitalise on newly learned communication skills, and the second after module 9 (early in phase three) to facilitate trauma-focused cognitive work. The MDMA sessions were delivered with two therapists present throughout; sessions alternated between time spent "inside" (participants reclining with eyeshades and pre-selected instrumental music) and time "outside" (speaking with partner and therapists) over an approximately six-hour period. Hourly subjective units of distress (SUDS) ratings and safety checks (blood pressure and temperature) were recorded. Participants stayed overnight at the study facility and received daily phone check-ins for seven days after each session. Dosing was by oral capsule: first session initial dose 75 mg with an optional 37.5 mg supplemental dose at 90 minutes (both participants took the supplement); second session offered initial 75 mg or 100 mg (both chose 100 mg) with a 50 mg supplemental dose. Participants fasted from midnight before sessions and received MDMA by 11:00 AM. Ethics approval was obtained from institutional review boards in the US and Canada and written informed consent was secured. Assessments were conducted by independent raters at baseline, post-treatment, three-month and six-month follow-ups. Primary outcomes were PTSD symptoms and relationship satisfaction measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), the PTSD Checklist for DSM-5 (PCL-5; patient and partner versions), and a one-item Couples Satisfaction Index (CSI) administered at each session. Inclusion criteria required participants to be aged over 18, with one partner meeting PTSD diagnostic criteria and the other partner not having PTSD. Exclusionary criteria for both partners included current substance use disorder, active suicidal planning or intent, mania, psychosis, and severe partner aggression; medical screening and tapering off psychiatric medications were required. The extracted text does not provide a broader sample size for the pilot trial within this section beyond noting that this article reports a single couple selected as a representative case. Therapists included one female clinician with CBCT expertise and one male clinician experienced with MDMA-assisted psychotherapy; both trained in the other modality to support integration of approaches. Some CBCT modules were condensed and some delivered via videoconference for pragmatic reasons; CBCT had previously been shown to be feasible via videotherapy.

The case involved a mid-50s married couple, described as Stuart (diagnosed with PTSD) and his wife Josie. At baseline Stuart's CAPS-5 score was 43 (scale 0–80), his self-rated PCL-5 score was 66 (scale 0–80), and his one-item CSI relationship satisfaction score was 3 (scale 0–6). Josie had no psychiatric diagnoses on the SCID-5; she rated Stuart's symptoms on the PCL-5 as 53 and rated relationship satisfaction as 3. Stuart had a history of repeated childhood sexual assault by his father and his father's colleagues, prior episodes of major depressive disorder and past alcohol use disorder, and previous EMDR but no prior cognitive–behavioural PTSD treatment. Across the integrated CBCT + MDMA course, phase one addressed psychoeducation and safety; phase two emphasised communication skills (used to prime sharing during MDMA sessions); phase three worked on dyadic cognitive restructuring of stuck thoughts. During the first MDMA session Stuart spontaneously narrated traumatic memories in chronological detail, remained with the sensory and emotional material, and experienced strong affect and some visceral physiological reactions (muscle tightening, sweating) without attempting to escape. Josie reported relaxation and greater ease in discussing impacts on the relationship. Both partners reported subjective gains after the first MDMA session, and completed behavioural approach tasks in the weeks before the second MDMA session. The second MDMA session produced similar processes; Stuart experienced periods of peace and pleasurable affect by the end of his second session. Objective outcomes showed large reductions in PTSD symptoms and improved relationship satisfaction. At post-treatment Stuart's CAPS-5 score was 1 and his PCL-5 score was 4; Josie's PCL-5 rating of Stuart's symptoms was 1. Both partners rated relationship satisfaction as 5 at post-treatment. These improvements were reported to be maintained at three- and six-month follow-ups. No significant adverse emotional or physiological sequelae were reported in the days following the MDMA sessions beyond transient fatigue in Stuart; participants adhered to the protocol and engaged in out-of-session assignments. Selective participant quotations reported in the text include Josie's description of feeling "overall inner peace—it's amazing," and Stuart's later comment that he had regained hope and felt as if a "light has been shined into the darkness of my soul."

Wagner and colleagues interpret this case as demonstrating that CBCT combined with MDMA-assisted sessions was feasible, well tolerated, and associated with marked reductions in PTSD symptoms and improved relationship satisfaction for this couple. They suggest that the intensive format—multiple full-day sessions, shared therapeutic rituals, the empathy-inducing effects attributed to MDMA, and close therapist contact—may have strengthened therapeutic bonds and supported engagement. For Stuart, the intervention appeared to facilitate a clearer understanding and acceptance of traumatic events, which the investigators argue disrupted avoidance and numbing and allowed memories to be examined with curiosity rather than fear. For Josie, the intervention reduced anxiety about engaging with Stuart's trauma and relieved the sense of "walking on eggshells." The authors highlight the value of combining an evidence-based, trauma-focused dyadic therapy (CBCT) with MDMA rather than using non-directive supportive psychotherapy alone, noting that the CBCT skills provided a common language and practical tools for ongoing integration. They also discuss implementation considerations: modules can be condensed and parts of CBCT delivered by videoconference; the therapeutic set, setting and broader context used for MDMA medicine are important design features but their individual contributions have not been isolated. The authors acknowledge the main limitation of this report—they present a single case from a pilot trial—so generalisability is unknown, and further research is required to determine whether these findings replicate in other couples. They therefore call for additional studies to evaluate safety, efficacy, and the relative contributions of CBCT, MDMA dosing, set and setting, and delivery format in larger, controlled samples.